Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 285 full-time employees. The company went IPO on 2018-09-14. The firm is also engaged in the commercialization of HuaTangNing products. The Company’s main product pipeline dorzagliatin or HMS5552 is a glucokinase activator or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The firm mainly conducts its business in the domestic market.
02552.HK stock price ended at $3.12 on 星期四, after dropping 0.64%
On the latest trading day Feb 12, 2026, the stock price of 02552.HK fell by 0.64%, dropping from $3.14 to $3.12. During the session, the stock saw a volatility of 4.30%, with prices oscillating between a daily low of $3.02 and a high of $3.15. On the latest trading day, the trading volume for 02552.HK decreased by 56.5K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 1.6M shares were traded, with a market value of approximately $3.0B.